Blood cancer (ALL leukaemia)
This study is a new type of treatment for B-Acute Lymphoblastic leukemia (a type of Blood Cancer) by using the patients own modified immune cells to target the cancer
Who can joinChildren and adults
Age3–25 years
Kind of studyPhase 2: does it work?
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial CentreNavi Mumbai, MaharashtraDirections ↗
Registry summary (technical)
Evaluating Efficacy and Safety of HCAR19 in pediatric, adolescents and young adults with relapsed/ refractory B- Acute lymphoblastic leukemia (ESHA) - A Phase Ib/II Clinical Trial. - ESHA Ib/II
Sponsor: Tata Memorial Hospital Research Administrative Council
CTRI/2023/03/050689 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 14 Sep 2026 · read by us 5 Nov 2026